ArticleOncology2015
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.
Article in Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pooled it
- Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis.Lipids in health and disease · 2015Pooled it
- The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- New advances of adiponectin in regulating obesity and related metabolic syndromes.Journal of pharmaceutical analysis · 2024Review
- Reappraisal of the Roles of the Sonic Hedgehog Signaling Pathway in Hepatocellular Carcinoma.Cancers · 2024Review
- Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.Cancers · 2023Review
- The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study.Frontiers in oncology · 2022Article
- Review
- Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.International journal of molecular sciences · 2021Review
- Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?International journal of molecular sciences · 2020Review
- The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Fatty changes associated with N-Nitrosodiethylamine (DEN) induced hepatocellular carcinoma: a role of sonic hedgehog signaling pathway.Genes & cancer · 2020Article
- Adiponectin Suppresses Human Pancreatic Cancer Growth through Attenuating the β-Catenin Signaling Pathway.International journal of biological sciences · 2019Article
- Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review.Journal of ophthalmology · 2018Review
- Global Level of Plasma DNA Methylation is Associated with Overall Survival in Patients with Hepatocellular Carcinoma.Annals of surgical oncology · 2017Article
- The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.Virulence · 2017Article
- Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.International journal of molecular sciences · 2017Review
- Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.Anticancer research · 2016Article
- The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials.BBA clinical · 2016Review
- Evolving role of adiponectin in cancer-controversies and update.Cancer biology & medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The rise in metabolic syndrome has contributed to this trend. Adipokines, such as adiponectin, are associated with prognosis in several cancers, but have not been well studied in HCC.
methodsWe prospectively enrolled 140 patients with newly diagnosed or recurrent HCC with Child-Pugh (CP) class A or B cirrhosis. We examined associations between serum adipokines, clinicopathological features of HCC, and time to death. We also examined a subset of tumors with available pathology for tissue adiponectin receptor (AR) expression by immunohistochemistry.
resultsThe median age of subjects was 62 years; 79% were men, 59% had underlying hepatitis C, and 36% were diabetic. Adiponectin remained a significant predictor of time to death (hazard ratio 1.90; 95% confidence interval 1.05-3.45; p = 0.03) in a multivariable adjusted model that included age, alcohol history, CP class, stage, and serum α-fetoprotein level. Cytoplasmic AR expression (AR1 and AR2) in tumors trended higher in those with higher serum adiponectin levels and in those with diabetes mellitus, but the association was not statistically significant.
conclusionsIn this hypothesis-generating study, we found the serum adiponectin level to be an independent predictor of overall survival in a diverse cohort of HCC patients. IMPACT: Understanding how adipokines affect the HCC outcome may help develop novel treatment and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.